Table 1.
Baseline Clinical Features of Patients Hopitalized With COVID‐19, Overall Population, Patients Receiving Prophylactic Anticoagulation With or Without Aspirin
| General population | Prophylactic anticoagulation | Prophylactic anticoagulation and aspirin | P value | |
|---|---|---|---|---|
| No. patients | 7824 | 2949 | 360 | |
| Age,y (means+SD) | 64±16 | 64±16 | 73±11 | <0.01* |
| Male | 58% | 58% | 69% | <0.01* |
| Baseline clinical profile | ||||
| Hypertension | 48% | 45% | 81% | <0.01* |
| Diabetes | 19% | 19% | 38% | <0.01* |
| Obesity (BMI >30) | 19% | 20% | 23% | 0.18 |
| Chronic kidney disease (Cl‐Cr <30 mL/min) | 6%* | 5% | 13% | <0.01* |
| History of lung disease | 18% | 17% | 26% | <0.01* |
| History of heart disease | 22% | 13% | 66% | <0.01* |
| History of cancer | 13% | 12% | 17% | <0.01* |
| In‐hospital complications | ||||
| Thromboembolic events | 2.6% | 2% | 3% | 0.52 |
| Bleeding | 2.3% | 2% | 2% | 0.57 |
| Invasive ventilation | 8.4% | 10% | 9% | 0.85 |
| Death | 18% | 17% | 18% | 0.86 |
BMI indicates body mass index; Cl‐Cr, clearance of creatinine; and PAC, prophylactic anticoagulation.
*
Indicates statistically significant.